Lower CMS Payment Rate Could Affect Royalties, BG Medicine Says | GenomeWeb

NEW YORK (GenomeWeb News) – Royalty payments received by BG Medicine from its development and commercialization partners may be reduced following the establishment of a payment rate for the firm's galectin-3 test by the US Centers for Medicare and Medicaid Services, the company said recently in its Form 10-K.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.